Skip to main content
Top
Published in: Endocrine 3/2011

01-06-2011 | Original Article

Vertebral fractures in males with prolactinoma

Authors: Gherardo Mazziotti, Teresa Porcelli, Marilda Mormando, Ernesto De Menis, Antonio Bianchi, Carola Mejia, Tatiana Mancini, Laura De Marinis, Andrea Giustina

Published in: Endocrine | Issue 3/2011

Login to get access

Abstract

Data on osteoporotic fractures in hyperprolactinemia are limited. An increased prevalence of radiological vertebral fractures was recently observed in women with prolactin (PRL)-secreting adenoma, whereas it is unknown whether this observation may reflect a more general increased risk of fractures in this disease and whether the prevalence of fractures in males is affected by gonadal status. Thirty-two males (median age 47 years, range: 22–79) with PRL-secreting pituitary adenoma (10 with microadenoma and 22 with macroadenoma) and 64 control males, with normal PRL values and with comparable age to patients with hyperprolactinemia, were evaluated for vertebral fractures by a morphometric approach and for bone mineral density (BMD) by a dual-energy X-ray absorptiometry at lumbar spine. Vertebral fractures were shown in 12 patients with PRL-secreting adenoma (37.5%) and in 5 controls (7.8%, P < 0.001). Fractured patients had lower BMD T-score (P = 0.007) and longer duration of disease (P < 0.001) as compared to patients who did not fracture. Fractures occurred more frequently (P = 0.03) in patients with untreated hyperprolactinemia versus patients treated with cabergoline whose frequency of vertebral fractures was still higher than control subjects. The prevalence of vertebral fractures was not significantly different between eugonadal and hypogonadal patients (33.3% vs. 38.5%; P = 0.8). Moreover, no significant (P = 0.4) difference in serum testosterone values was found between fractured and not fractured males. Hyperprolactinemia is associated with high prevalence of radiological vertebral fractures in men with PRL-secreting adenoma. These findings would also suggest that PRL excess may produce negative skeletal effects independently of hypogonadism.
Literature
1.
go back to reference F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006)CrossRef F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein, T. Brue, P. Cappabianca, A. Colao, R. Fahlbusch, H. Fideleff, M. Hadani, P. Kelly, D. Kleinberg, E. Laws, J. Marek, M. Scanlon, L.G. Sobrinho, J.A. Wass, A. Giustina, Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. 65, 265–273 (2006)CrossRef
2.
go back to reference A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72, 377–382 (2010)CrossRef A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. 72, 377–382 (2010)CrossRef
3.
go back to reference T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008)PubMedCrossRef T. Mancini, F.F. Casanueva, A. Giustina, Hyperprolactinemia and prolactinomas. Endocrinol. Metab. Clin. North Am. 37, 67–99 (2008)PubMedCrossRef
4.
go back to reference S.L. Greenspan, R.M. Neer, E.C. Ridgway, A. Klibanski, Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 104, 777–782 (1986)PubMed S.L. Greenspan, R.M. Neer, E.C. Ridgway, A. Klibanski, Osteoporosis in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 104, 777–782 (1986)PubMed
5.
go back to reference S.L. Greenspan, D.S. Oppenheim, A. Klibanski, Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 110, 526–531 (1989)PubMed S.L. Greenspan, D.S. Oppenheim, A. Klibanski, Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann. Intern. Med. 110, 526–531 (1989)PubMed
6.
go back to reference A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104 (2009)PubMedCrossRef A. Shibli-Rahhal, J. Schlechte, The effects of hyperprolactinemia on bone and fat. Pituitary 12, 96–104 (2009)PubMedCrossRef
7.
go back to reference P. Vestergaard, J.O. Jørgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, J. Weeke, M. Andersen, F.L. Conceicao, T.L. Nielsen, L. Mosekilde, Fracture risk is increased in patients with GH deficiency or untreated prolactinomas—a case-control study. Clin. Endocrinol. 56, 159–167 (2002)CrossRef P. Vestergaard, J.O. Jørgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, J. Weeke, M. Andersen, F.L. Conceicao, T.L. Nielsen, L. Mosekilde, Fracture risk is increased in patients with GH deficiency or untreated prolactinomas—a case-control study. Clin. Endocrinol. 56, 159–167 (2002)CrossRef
8.
go back to reference G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. (2011). [Epub ahead of print] PubMed PMID: 21301967 G. Mazziotti, T. Mancini, M. Mormando, E. De Menis, A. Bianchi, M. Doga, T. Porcelli, P.P. Vescovi, L. De Marinis, A. Giustina, High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. Pituitary. (2011). [Epub ahead of print] PubMed PMID: 21301967
9.
go back to reference G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRef G. Mazziotti, E. Canalis, A. Giustina, Drug-induced osteoporosis: mechanisms and clinical implications. Am. J. Med. 123, 877–884 (2010)PubMedCrossRef
10.
go back to reference J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National osteoporosis guideline group: case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)PubMedCrossRef J.A. Kanis, E.V. McCloskey, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National osteoporosis guideline group: case finding for the management of osteoporosis with FRAX–assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)PubMedCrossRef
11.
go back to reference J.A. Kanis, N. Burlet, C. Cooper, P.D. Delmas, J.Y. Reginster, F. Borgstrom, R. Rizzoli, European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO): European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399–428 (2008)PubMedCrossRef J.A. Kanis, N. Burlet, C. Cooper, P.D. Delmas, J.Y. Reginster, F. Borgstrom, R. Rizzoli, European society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO): European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos. Int. 19, 399–428 (2008)PubMedCrossRef
12.
go back to reference H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984–996 (1996)PubMedCrossRef H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in the osteoporosis. The Study of Osteoporotic Fractures Research Group. J. Bone Miner. Res. 11, 984–996 (1996)PubMedCrossRef
13.
go back to reference M.C. Nevitt, B. Black, D.M. Black, K. Stone, S.A. Jamal, K. Ensrud, M. Segal, H.K. Genant, S.R. Cummings, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 128, 793–800 (1998)PubMed M.C. Nevitt, B. Black, D.M. Black, K. Stone, S.A. Jamal, K. Ensrud, M. Segal, H.K. Genant, S.R. Cummings, The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann. Intern. Med. 128, 793–800 (1998)PubMed
14.
go back to reference T. Jalava, S. Sarna, L. Pylkkänen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003)PubMedCrossRef T. Jalava, S. Sarna, L. Pylkkänen, B. Mawer, J.A. Kanis, P. Selby, M. Davies, J. Adams, R.M. Francis, J. Robinson, E. McCloskey, Association between vertebral fracture and increased mortality in osteoporotic patients. J. Bone Miner. Res. 18, 1254–1260 (2003)PubMedCrossRef
15.
go back to reference J.A. Schlechte, B. Sherman, R. Martin, Bone density in amenorrheic women with and without hyperprolactinemia. J. Clin. Endocrinol. Metab. 56, 1120–1123 (1983)PubMedCrossRef J.A. Schlechte, B. Sherman, R. Martin, Bone density in amenorrheic women with and without hyperprolactinemia. J. Clin. Endocrinol. Metab. 56, 1120–1123 (1983)PubMedCrossRef
16.
go back to reference D. Coss, L. Yang, C.B. Kuo, X. Xu, R.A. Luben, A.M. Walker, Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 279, E1216–E1225 (2000)PubMed D. Coss, L. Yang, C.B. Kuo, X. Xu, R.A. Luben, A.M. Walker, Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am. J. Physiol. Endocrinol. Metab. 279, E1216–E1225 (2000)PubMed
17.
go back to reference S. Lotinun, L. Limlomwongse, V. Sirikulchayanonta, N. Krishnamra, Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 20, 163–170 (2003)PubMedCrossRef S. Lotinun, L. Limlomwongse, V. Sirikulchayanonta, N. Krishnamra, Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 20, 163–170 (2003)PubMedCrossRef
18.
go back to reference D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J. Cell. Biochem. 107, 677–685 (2009)PubMedCrossRef D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J. Cell. Biochem. 107, 677–685 (2009)PubMedCrossRef
19.
go back to reference D. Seriwatanachai, N. Charoenphandhu, T. Suthiphongchai, N. Krishnamra, Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol. Intern. 32, 1126–1135 (2008)CrossRef D. Seriwatanachai, N. Charoenphandhu, T. Suthiphongchai, N. Krishnamra, Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol. Intern. 32, 1126–1135 (2008)CrossRef
20.
go back to reference D. Seriwatanachai, K. Thongchote, N. Charoenphandhu, J. Pandaranandaka, K. Tudpor, J. Teerapornpuntakit, T. Suthiphongchai, N. Krishnamra, Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 42, 535–546 (2008)PubMedCrossRef D. Seriwatanachai, K. Thongchote, N. Charoenphandhu, J. Pandaranandaka, K. Tudpor, J. Teerapornpuntakit, T. Suthiphongchai, N. Krishnamra, Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone. 42, 535–546 (2008)PubMedCrossRef
21.
go back to reference S.C. Schuit, M. van der Klift, A.E. Weel, C.E. de Laet, H. Burger, E. Seeman, A. Hofman, A.G. Uitterlinden, J.P. van Leeuwen, H.A. Pols, Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34, 195–202 (2004)PubMedCrossRef S.C. Schuit, M. van der Klift, A.E. Weel, C.E. de Laet, H. Burger, E. Seeman, A. Hofman, A.G. Uitterlinden, J.P. van Leeuwen, H.A. Pols, Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone 34, 195–202 (2004)PubMedCrossRef
22.
go back to reference G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)PubMedCrossRef G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)PubMedCrossRef
23.
go back to reference P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)PubMedCrossRef P. Vestergaard, Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes–a meta-analysis. Osteoporos. Int. 18, 427–444 (2007)PubMedCrossRef
24.
go back to reference T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 45, 784–788 (2009)PubMedCrossRef T. Mancini, G. Mazziotti, M. Doga, R. Carpinteri, N. Simetovic, P.P. Vescovi, A. Giustina, Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. Bone. 45, 784–788 (2009)PubMedCrossRef
25.
go back to reference G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco, A. Pontecorvi, L. De Marinis, A. Giustina, Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008)PubMedCrossRef G. Mazziotti, A. Bianchi, S. Bonadonna, V. Cimino, I. Patelli, A. Fusco, A. Pontecorvi, L. De Marinis, A. Giustina, Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93, 4649–4655 (2008)PubMedCrossRef
26.
go back to reference G. Mazziotti, T. Porcelli, I. Patelli, P.P. Vescovi, A. Giustina, Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46, 747–751 (2010)PubMedCrossRef G. Mazziotti, T. Porcelli, I. Patelli, P.P. Vescovi, A. Giustina, Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density. Bone 46, 747–751 (2010)PubMedCrossRef
27.
go back to reference E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)PubMedCrossRef E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357, 905–916 (2007)PubMedCrossRef
28.
go back to reference G. Iván, N. Szigeti-Csúcs, M. Oláh, G.M. Nagy, M.I. Góth, Treatment of pituitary tumors: dopamine agonists. Endocrine. 28, 101–110 (2005)PubMedCrossRef G. Iván, N. Szigeti-Csúcs, M. Oláh, G.M. Nagy, M.I. Góth, Treatment of pituitary tumors: dopamine agonists. Endocrine. 28, 101–110 (2005)PubMedCrossRef
29.
go back to reference C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M.L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, G. Lombardi, Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. 83, 807–813 (1998)PubMedCrossRef C. Di Somma, A. Colao, A. Di Sarno, M. Klain, M.L. Landi, G. Facciolli, R. Pivonello, N. Panza, M. Salvatore, G. Lombardi, Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. 83, 807–813 (1998)PubMedCrossRef
30.
go back to reference A. Colao, C. Di Somma, S. Loche, A. Di Sarno, M. Klain, R. Pivonello, M. Pietrosante, M. Salvatore, G. Lombardi, Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. 52, 319–327 (2000)CrossRef A. Colao, C. Di Somma, S. Loche, A. Di Sarno, M. Klain, R. Pivonello, M. Pietrosante, M. Salvatore, G. Lombardi, Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin. Endocrinol. 52, 319–327 (2000)CrossRef
31.
go back to reference A. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano, O. Alfieri, Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am. Heart J. 131, 620–622 (1996)PubMedCrossRef A. Giustina, R. Lorusso, V. Borghetti, G. Bugari, V. Misitano, O. Alfieri, Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am. Heart J. 131, 620–622 (1996)PubMedCrossRef
32.
go back to reference E. Ghigo, G. Aimaretti, E. Arvat, F. Camanni, Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 15, 29–38 (2001)PubMedCrossRef E. Ghigo, G. Aimaretti, E. Arvat, F. Camanni, Growth hormone-releasing hormone combined with arginine or growth hormone secretagogues for the diagnosis of growth hormone deficiency in adults. Endocrine. 15, 29–38 (2001)PubMedCrossRef
33.
go back to reference M. Doga, S. Bonadonna, M. Gola, S.B. Solerte, G. Amato, C. Carella, A. Giustina, Current guidelines for adult GH replacement. Rev. Endocr. Metab. Disord. 6, 63–70 (2005)PubMedCrossRef M. Doga, S. Bonadonna, M. Gola, S.B. Solerte, G. Amato, C. Carella, A. Giustina, Current guidelines for adult GH replacement. Rev. Endocr. Metab. Disord. 6, 63–70 (2005)PubMedCrossRef
34.
go back to reference A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCrossRef A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008)PubMedCrossRef
35.
go back to reference G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)PubMedCrossRef G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006)PubMedCrossRef
36.
go back to reference G. Mazziotti, A. Bianchi, V. Cimino, S. Bonadonna, P. Martini, A. Fusco, L. De Marinis, A. Giustina, Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary. 11, 55–61 (2008)PubMedCrossRef G. Mazziotti, A. Bianchi, V. Cimino, S. Bonadonna, P. Martini, A. Fusco, L. De Marinis, A. Giustina, Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. Pituitary. 11, 55–61 (2008)PubMedCrossRef
Metadata
Title
Vertebral fractures in males with prolactinoma
Authors
Gherardo Mazziotti
Teresa Porcelli
Marilda Mormando
Ernesto De Menis
Antonio Bianchi
Carola Mejia
Tatiana Mancini
Laura De Marinis
Andrea Giustina
Publication date
01-06-2011
Publisher
Springer US
Published in
Endocrine / Issue 3/2011
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-011-9462-5

Other articles of this Issue 3/2011

Endocrine 3/2011 Go to the issue